Semaglutide vs. Tirzepatide via Telehealth: Which Should You Choose?
Semaglutide and tirzepatide are the two GLP-1 medications available through telehealth in 2026. Both produce significant weight loss. Both are injectable (with emerging oral options). But they work differently, cost differently, and produce different results. Here's what the clinical data actually shows — and how to decide which one is right for you.
The Mechanisms: Single vs. Dual Agonist
Semaglutide (brand names: Wegovy, Ozempic) is a GLP-1 receptor agonist. It mimics the GLP-1 hormone your gut naturally produces after eating, which tells your brain you're full, slows stomach emptying, and reduces appetite. One mechanism, one hormone pathway.
Tirzepatide (brand names: Zepbound, Mounjaro) is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 pathway and the GIP (glucose-dependent insulinotropic polypeptide) pathway. GIP is involved in fat metabolism and insulin sensitivity — so tirzepatide attacks weight from two biological angles simultaneously.
Think of it this way: semaglutide turns down your appetite. Tirzepatide turns down your appetite and changes how your body processes and stores fat.
Weight Loss: The Numbers
The SURMOUNT-5 trial (2024) directly compared tirzepatide vs. semaglutide for the first time in a randomized, head-to-head study. The results were clear:
Tirzepatide: 20.2% average body weight loss over 72 weeks.
Semaglutide: 13.7% average body weight loss over 72 weeks.
That's a 47% greater weight loss with tirzepatide. For a 250-lb patient, that translates to roughly 50 lbs lost on tirzepatide vs. 34 lbs on semaglutide. Both are clinically meaningful — but tirzepatide consistently outperforms in every trial published to date.
Earlier trials showed similar patterns. SURMOUNT-1 (tirzepatide) showed up to 22.5% weight loss at the highest dose, while STEP 1 (semaglutide) showed 14.9%. The gap has been consistent across multiple study designs.
Side Effects: How They Compare
Both medications share the same primary side effect profile: GI symptoms including nausea, vomiting, diarrhea, and constipation. These typically peak during dose titration and fade over time.
Semaglutide side effects (from STEP trials): Nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Most resolve within weeks.
Tirzepatide side effects (from SURMOUNT trials): Nausea (31%), diarrhea (23%), vomiting (12%), constipation (17%). Generally lower rates than semaglutide.
Tirzepatide actually produces fewer GI side effects than semaglutide despite stronger weight loss results. This is counterintuitive — you'd expect more aggressive weight loss to come with more side effects — and it's one of the reasons clinicians have gravitated toward tirzepatide for patients who can access it.
Cost Through Telehealth
| Option | Semaglutide | Tirzepatide |
|---|---|---|
| Compounded (telehealth) | $146-250/mo | $258-350/mo |
| Brand retail (no insurance) | $1,349/mo | $1,080/mo |
| Brand w/ savings program | $149-590/mo | $299-449/mo |
| Brand oral (pill) | $149/mo (Wegovy pill) | Not available |
Tirzepatide costs $50-100/mo more than semaglutide through compounded telehealth providers. Through brand-name channels, tirzepatide (Zepbound) is actually cheaper at retail than semaglutide (Wegovy), though manufacturer discount pricing varies.
Decision Framework
Choose Semaglutide If...
Budget is your primary concern. At $146-199/mo for compounded semaglutide, it's the most affordable entry point to GLP-1 treatment. If the $50-100/mo difference matters to your finances, semaglutide delivers strong results at a lower price.
You want an oral option. The oral Wegovy pill (launched 2026) is the first convenient pill-form GLP-1 for weight management, priced at $149/mo through NovoCare. Tirzepatide has no FDA-approved oral form yet.
You have insurance that covers Wegovy. Semaglutide has been on the market longer, and more insurance plans cover Wegovy than Zepbound. If your plan covers one but not the other, that may settle the decision.
Yucca Health — $146/mo
Lowest intro price · semaglutide & tirzepatide
Sponsored · Compounded medications are not FDA-approved.
Choose Tirzepatide If...
Maximum weight loss is your goal. The data is unambiguous: tirzepatide produces ~47% more weight loss than semaglutide. If you're targeting significant weight reduction and can afford the premium, tirzepatide is the stronger clinical choice.
You've plateaued on semaglutide. Some patients who stall on semaglutide see renewed progress after switching to tirzepatide. The dual mechanism (GLP-1 + GIP) may unlock additional metabolic pathways that semaglutide alone can't reach.
Side effects concern you. Counterintuitively, tirzepatide produces fewer GI side effects than semaglutide in clinical trials. If you're worried about nausea, tirzepatide may actually be the gentler option.
Synergy Rx — $200/mo
All-inclusive compounded semaglutide & tirzepatide
Sponsored · Compounded medications are not FDA-approved.
Can You Switch Between Them?
Yes. Switching from semaglutide to tirzepatide (or vice versa) is medically straightforward. Your prescribing provider will adjust your dose based on what you were taking and restart titration on the new medication. Most telehealth providers can handle this switch within a single follow-up consultation. There's no medical reason you can't try one and switch to the other if it's not working for you.
The Verdict
If money were no object, tirzepatide wins on the data. It produces more weight loss with fewer side effects in every head-to-head comparison. But semaglutide is the better value at $50-100/mo less, and it has a longer clinical track record, more insurance coverage, and an oral option. Most patients will do well on either medication — the best choice is the one you can afford, access reliably, and stay on consistently.